CBD & pathways
CBD molecular targets: TRPV1, 5-HT1A, PPAR-γ, GPR55 and adenosine
How cannabidiol is studied beyond CB1 and CB2, with receptor biology, chemical formulae and a careful separation of cell experiments from human evidence.
Published experiments support several plausible targets. Affinity, concentration and tissue exposure vary; a target found in a dish may not be engaged by an uncharacterised retail formulation.
Compounds & molecular formulae
Cannabidiol (CBD)
C₂₁H₃₀O₂
A non-intoxicating phytocannabinoid in the cannabis plant; the formula is shared with THC but the structures and pharmacology differ.
PubChem compound record ↗Capsaicin (TRPV1 probe)
C₁₈H₂₇NO₃
A laboratory agonist often used to test TRPV1 sensory signalling; it is not an ingredient claim for Enki oil.
PubChem compound record ↗One molecule, several experimental doors
- CBD reaches a membrane or receptor system
- Target-specific binding or channel modulation
- Second messengers change (Ca²⁺, cAMP or transcription)
- A cell, animal or human endpoint is measured
The final step is the one that determines whether a proposed mechanism translates into a meaningful human outcome [1][2][3].
TRPV1 opening → Na⁺/Ca²⁺ influx → depolarisation → sensory signalling
TRPV1 is a non-selective cation channel. CBD can influence TRPV1-related experiments, but the direction and effect depend on concentration and assay.
ENT1 inhibition → extracellular adenosine ↑ → A₂A signalling
A 2006 mouse/microglia study linked CBD inhibition of ENT1 to enhanced adenosine signalling. It is an interesting pathway, not a general human anti-inflammatory prescription.
CBD is not just a CB1 story
CBD has low direct activity at the classical cannabinoid receptors compared with THC, and it does not produce THC’s typical intoxicating CB1 agonism. In laboratory systems, CBD can act as a negative allosteric modulator of CB1, changing how another ligand signals rather than occupying the same orthosteric site [1]. Other experiments describe modest agonism at human 5-HT1A receptors [2], activity at TRPV1, PPAR-γ and GPR55, and inhibition of equilibrative nucleoside transporter 1 (ENT1) with downstream A₂A adenosine signalling [3].
Why receptor names are not treatment claims
A receptor can be found in a pathway without being a useful therapeutic target at the exposure achieved by a product. Cell lines may use micromolar concentrations, overexpress a receptor or remove metabolism and tissue barriers. Human pharmacology adds absorption, protein binding, active metabolites and individual variation. Even a validated target may produce different effects with topical, oral, inhaled or prescription formulations. These caveats are why the FDA-approved CBD medicine Epidiolex has a defined strength, indication, monitoring and interaction information; a general hemp oil should not borrow that label.
Read the pathway with the endpoint
For a mechanistic paper, ask what was actually measured: calcium current, cAMP, phosphorylation, cytokines, behaviour or a validated clinical scale. Ask whether the experiment was in a purified protein, a cell, an animal or humans. A lower cytokine in a mouse after an injected compound is not the same as improved function in a Kenyan customer using an oil. Enki’s science articles show the pathway and the evidence level together so readers can see where the inference begins.
Sources & credits
- Laprairie et al. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor (British Journal of Pharmacology, 2015) — Primary cell and receptor study
- Russo et al. Agonistic properties of cannabidiol at 5-HT1A receptors (Neurochemical Research, 2005) — Primary receptor study
- Carrier et al. Inhibition of an equilibrative nucleoside transporter by cannabidiol (PNAS, 2006) — Primary microglia and mouse study
- FDA/DailyMed: EPIDIOLEX cannabidiol oral solution label — Prescription-label context